Mentice AB (MN2) Stock Price & Analysis
MN2 Stock Chart & Stats
- Day’s Range
- EUR 1.37 - EUR 1.37
- 52-Week Range
- EUR 0.83 - EUR 1.51
- Previous Close
- EUR 1.42
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 39.59M
- Enterprise Value
- EUR 325.16M
- Total Cash (Recent Filing)
- EUR 61.07M
- Total Debt (Recent Filing)
- EUR 13.56M
- Price to Earnings (P/E)
- ―
- Beta
- 0.94
- Next Earnings
- Nov 10, 2026 (Est.)
- EPS Estimate
- -0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improving Revenue Trajectory
Stronger TTM revenue growth indicates improving demand for Mentice’s simulation and training offering. If sustained, broader adoption across hospitals, training centers, and medical device customers can support operating leverage and provide a durable foundation for future earnings improvement.
Conservative Balance Sheet
Low leverage and a substantial equity base give Mentice financial flexibility to support product development, customer deployments, and strategic investment without relying heavily on debt. This conservative capital structure also improves resilience if operating conditions weaken.
TTM Cash Generation Recovery
The return to positive operating and free cash flow is an important improvement in the company’s ability to fund operations internally. Sustained cash conversion would reduce dependence on external financing and provide more flexibility for investment in software, content, and customer support.
Bears Say
Persistent Operating Losses
Mentice has improved its profitability trend but has not yet reached consistent bottom-line profitability. Continued EBIT and net losses can limit internally funded growth, weaken returns on invested capital, and make future performance more dependent on successful execution and revenue expansion.
Volatile Cash Flow
Although TTM cash generation is positive, the pronounced year-to-year volatility makes the company’s funding capacity less predictable. Inconsistent cash conversion can complicate investment planning and reduce confidence that reported revenue growth will translate reliably into durable free cash flow.
Negative Returns On Equity
Negative ROE shows that the existing equity base is not yet generating positive returns because losses continue. Until profitability improves, capital efficiency remains weak, which can constrain the quality of growth and reduce the long-term benefits of Mentice’s otherwise conservative leverage.
Mentice AB News
MN2 FAQ
What was Mentice AB’s price range in the past 12 months?
What is Mentice AB’s market cap?
When is Mentice AB’s upcoming earnings report date?
How were Mentice AB’s earnings last quarter?
Is Mentice AB overvalued?
Does Mentice AB pay dividends?
What is Mentice AB’s EPS estimate?
How many shares outstanding does Mentice AB have?
What happened to Mentice AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Mentice AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Mentice AB
Mentice AB (publ), founded in 1998 and headquartered in Gothenburg, Sweden, specializes in delivering advanced endovascular simulation solutions. These are utilized by educational institutions, healthcare systems, and medical device manufacturers globally, with the company's operations spanning across Europe, the Middle East, Africa, the Asia Pacific region, and the Americas. Its business is structured across distinct segments focusing on the Medical Device Industry, Healthcare Systems, and Strategic Alliances. The company offers a comprehensive suite of software modules designed for training in a wide array of interventional procedures. These include acute ischemic stroke, atrial septal defect/patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee, carotid, and renal interventions, along with patient-specific simulations. The portfolio further encompasses advanced and essential coronary procedures, intermediate coronary, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic and uterine artery embolization, radiation safety, transarterial chemoembolization, transseptal puncture, vascular trauma, and cardiac rhythm management. Additionally, Mentice provides crucial support for interventionalists transitioning from transfemoral to transradial access techniques. Beyond software, Mentice's product line features sophisticated medical simulators for endovascular therapies, accompanied by compatible accessories and extensions. They also supply specialized silicone vasculature, as well as cardiac, vascular, and neurovascular flow systems. Innovative digital offerings include the Mentice Right Heart Cath App, a mobile tool for interactive exploration of right heart catheterization procedures, and the Mentice Live Learning Center, which facilitates remote learning through its VIST G endovascular simulation platform. All these comprehensive solutions are engineered to educate, train, and significantly enhance the skills of medical professionals.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Frans Matthieu Venker
- Employees
- 109
- Website
- www.mentice.com
- Address
- Odinsgatan 10, Gothenburg, VG, 411 03, SE
Mentice AB (MN2) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 5 | 5 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 8 | 0 | 4 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| SE:GETI.BGetinge | ||
| SE:XVIVOXvivo Perfusion AB | ||
| SE:BACTI.BBactiguard Holding AB | ||
| SE:SECT.BSectra AB Class B | ||
| SE:HEARTScandinavian Real Heart AB |